The role of RUNX1 in MLL-AF4 leukaemia
The role of RUNX1 in MLL-AF4 leukaemia
批准号:
1960359
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
During the past decades advances in our understanding of the biology of paediatric acute lymphoblastic leukaemias and optimization of therapeutic protocols have led to survival rates up to 85%. However, childhood leukaemias caused by translocation of MLL (Mixed Lineage Leukaemia) gene and its fusion with different partner genes are characterized by poor survival rates. Leukaemias caused by MLL-AF4 fusion protein are the most frequent among the MLL rearranged leukaemias and are characterized by small number of cooperating mutations and a very short latency, which underlines the role of MLL as a driver in the process of leukaemogenesis.The goal of this project will be to elucidate the role of specific transcription factors, previously identified in the lab, to MLL leukaemogenesis. The transcription factors involved in leukaemogenesis fall into two classes: (i) transcription factors that are downstream targets of the MLL-AF4 fusion protein; these are upregulated in MLL rearranged leukaemias and contribute directly to leukaemogenesis; and (ii) transcription factors that are normally expressed in lymphoid cells, but their normal function is abrogated in leukaemia cells due to the altered chromatin landscape and epigenetic signatures caused by the fusion protein.The binding patterns of the identified transcription factors will be investigated by high-throughput methods including ChIP-sequencing in the SEM leukaemia cell line, which harbours the MLL-AF4 mutation. In this way I will investigate whether this is affected after treatment with small molecule inhibitors that abrogate leukaemic growth. In addition, the role of the identified transcription factors will be examined by performing knockdown experiments in the SEM cell line, in order to determine the effects on leukaemic growth. Furthermore, I will employ newly developed techniques, including CITE-Seq and REAP-Seq, that combine high-throughput single cell RNA-sequencing with cell surface protein detection. This will enable us to examine the expression of different transcription factors in primary MLL-AF4 cells, compared to normal B cells and B cell progenitors, and will provide valuable insight into the origin of MLL leukaemias and the molecular biology of the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
RUNX1通过BMP2/Smad信号轴调控肿瘤相关巨噬细胞M2极化促进膀胱癌进展的机制研究
-
批准号:2026JJ81626
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黎勇林
-
依托单位:
三尖刺血经RUNX1下调CMPK2磷酸化减轻Ox-mtDNA介导的小胶质细胞炎症反应治疗急性缺血性卒中的机制研究
-
批准号:2026JJ82023
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖靓宜
-
依托单位:
USP11/RUNX1正反馈环路抑制免疫原性细胞死亡促进结直肠癌进展的机制研究
-
批准号:JCZRQN202501352
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
化瘀解毒方调控RUNX1介导自噬依赖性NETosis改善急性脑梗死的机制研究
-
批准号:2025JJ50566
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李定祥
-
依托单位:
RUNX1 正向调控 CCL1-CCR8 轴诱导 ILC2 活化参与过敏性哮喘机制研究
-
批准号:2025JJ60715
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:蒋媛媛
-
依托单位:
RUNX1调控巨噬细胞M1极化及重编程促进糖尿病肾脏病进展的作用及分子机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:关美萍
-
依托单位:
基于RUNX1/RIP3MLKL内源性程序性坏死途径研究消瘤藤总善豆素抵抗肺癌EGFR-TKI耐药的作用机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:黎疆
-
依托单位:
功能性子宫内膜类器官靶向RUNX1调控TGF β1/SMAD3通路促进宫腔粘
连再生修复的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
转录因子RUNX1调控代谢重编程增强脂质合成促进肾透明细胞癌进展的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:30.0万元
-
批准年份:2024
-
负责人:邓煜麟
-
依托单位:
LINC02820介导RUNX1可变剪切增敏TNF/NF-κB信号促进食管鳞癌转移及免疫逃逸
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:黄必军
-
依托单位: